Full Schedule

6:30 AM - 6:00 PM AST

Registration & Badge Pickup

Location: Lobby

7:00 AM - 8:30 AM AST

ISS IX: A Treatment Approach for Certain Types of HER2+ Metastatic Solid Tumors After Prior Systemic Treatment

Location: 208

7:00 AM - 8:30 AM AST

ISS VIII: Administering an Antibody Drug Conjugate to Appropriate 2L+ Relapsed/Metastatic Cervical Cancer Patients

Location: Ballroom B

7:00 AM - 8:30 AM AST

ISS X: Breaking Barriers in Platinum-Resistant Ovarian Cancer: Novel Targets and Emerging Therapies

Location: 209

7:00 AM - 6:00 PM AST

Lactation Room

Location: 202A

7:00 AM - 6:00 PM AST

Speaker Ready Room

Location: 201B

7:30 AM - 5:00 PM AST

Exhibit Hall Open

Location: Exhibit Hall B

8:00 AM - 9:00 AM AST

Coffee Break in Exhibit Hall

Location: Exhibit Hall B

8:15 AM - 8:25 AM AST

Advancing Research Excellence - Foundation for Women’s Cancer

Location: SGO Booth (#323)

Speaker: – Foundation for Women's Cancer

8:30 AM - 9:00 AM AST

We're Listening! Help Us Build the Future of SGO Wellness!

Location: SGO Booth (#323)

Speaker: – Penn State Health

8:45 AM - 9:00 AM AST

Introduction & Overview Talk

Location: Exhibit Hall A

Speaker: – Icahn School of Medicine at Mount Sinai

Speaker: – University of Alabama at Birmingham

9:00 AM - 9:25 AM AST

Panel Discussion

Location: Exhibit Hall A

Panelist: – Emory University

Panelist: – Brigham & Women's Hospital/Dana Farber Cancer Institute

Panelist: – University Of Pennsylvania

9:25 AM - 9:30 AM AST

Q&A

Location: Exhibit Hall A

Moderator: – Icahn School of Medicine at Mount Sinai

Moderator: – University of Alabama at Birmingham

8:45 AM - 9:30 AM AST

Future of the Profession: Scope Creep or Scope Evolution? Redefining Gynecologic Oncology Sponsored by Gynecologic Oncology

Location: Exhibit Hall A

Speaker: – University of Alabama at Birmingham

Speaker: – Icahn School of Medicine at Mount Sinai

Live Streamed

8:50 AM - 9:00 AM AST

Scope Creep or Scope Evolution? Redefining Gynecologic Oncology

Speaker: – University of Alabama at Birmingham

Speaker: – Icahn School of Medicine at Mount Sinai

9:30 AM - 9:32 AM AST

Introduction

Location: Exhibit Hall A

Moderator: – Moffitt Cancer Center

9:32 AM - 10:00 AM AST

Breath by Breath: From Cancer to Everest

Location: Exhibit Hall A

Speaker:

Live Streamed

10:00 AM - 10:02 AM AST

Introduction

Location: Exhibit Hall A

Moderator: – University of California, San Francisco

Moderator: – The Ohio State University James Cancer Center

10:02 AM - 10:10 AM AST

Mocertatug rezetecan (GSK5733584), a B7-H4-targeted antibody-drug conjugate (ADC), in platinum-resistant ovarian cancer (PROC) and endometrial cancer (EC): First results from the global BEHOLD-1 study

Location: Exhibit Hall A

Speaker: – Hospital Universitario Puerta de Hierro Majadahond, Madrid

LBA

10:10 AM - 10:18 AM AST

SYS6043, a B7-H3 targeting antibody-drug conjugates in patients with advanced gynecologic cancers: a phase 1/2, first-in-human study

Location: Exhibit Hall A

Speaker: – National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy

10:18 AM - 10:26 AM AST

Updated results from the first-in-human phase 1 study of LY4170156, an antibody drug conjugate (ADC) targeting folate receptor alpha (FRÎ±) in recurrent platinum resistant high-grade serous ovarian cancer (HGSOC)

Location: Exhibit Hall A

Speaker: – Perlmutter Cancer Center, NYU Langone

10:26 AM - 10:34 AM AST

The pivotal PYNNACLE Phase 2 trial assessing rezatapopt, a selective p53 reactivator, in patients with advanced or metastatic solid tumors harboring a TP53 Y220C mutation: Interim analysis of patients with ovarian cancer

Location: Exhibit Hall A

Speaker: – Memorial Sloan Kettering Cancer Center

10:34 AM - 10:42 AM AST

Phase II Study of Camrelizumab plus Apatinib Combined with Chemotherapy in High-Risk, Chemoresistant Gestational Trophoblastic Neoplasia

Location: Exhibit Hall A

Speaker: – Peking Union Medical College Hospital

10:42 AM - 10:52 AM AST

Distillation

Location: Exhibit Hall A

Speaker: – Johns Hopkins Sidney Kimmel Cancer Center

10:52 AM - 11:00 AM AST

Q&A

Location: Exhibit Hall A

11:00 AM - 11:30 AM AST

From Intimidation to Influence: The Fellows Preview

Location: Fellows' Lounge - Exhibit Hall B

Speaker: – The University of Kansas Medical Center

Speaker: – Univerisity Hospitals Cleveland Medical Center

Speaker: – UMass Memorial Health

11:00 AM - 11:02 AM AST

Introduction

Location: Exhibit Hall B

Moderator: – The University of Texas MD Anderson Cancer Center

Moderator: – University of Alabama

11:02 AM - 11:09 AM AST

What will it take to make maintenance mirvetuximab soravtansine cost-effective in platinum-sensitive ovarian cancer: a threshold analysis

Location: Exhibit Hall B

Poster Presenter: – Duke University

Poster

11:09 AM - 11:16 AM AST

Survival trends in cervical cancer: A racial/ethnic comparison in the United States and Puerto Rico (2000-2021)

Location: Exhibit Hall B

Poster Presenter: – University of Puerto Rico Comprehensive Cancer Center

Poster

11:16 AM - 11:23 AM AST

Epidermic trends in female early-onset cancer: an analysis based on the Global Burden of Disease Study 1990-2021

Location: Exhibit Hall B

Poster Presenter: – Fujian cancer hospital

Poster

11:23 AM - 11:30 AM AST

Association of financial toxicity with ovarian cancer treatment and survival

Location: Exhibit Hall B

Poster Presenter: – Beth Israel Deaconess Medical Center

Poster

11:00 AM - 11:02 AM AST

Introduction

Location: Exhibit Hall B

Moderator: – University of Alabama at Birmingham

Moderator: – Memorial Sloan Kettering Cancer Center

11:02 AM - 11:09 AM AST

Exploratory Analysis of Ribociclib Plus Letrozole in Recurrent Low-Grade Serous Ovarian Carcinoma: Impact of Prior Therapy, Chemotherapy Exposure, and Age (GOG-3026)

Location: Exhibit Hall B

Poster Presenter: – Mount Sinai Medical Center

Poster

11:09 AM - 11:16 AM AST

Neoadjuvant Pamiparib in Newly Diagnosed Advanced Ovarian Cancer: A Single-Arm, Prospective Phase II Trial

Location: Exhibit Hall B

Poster Presenter: – Fujian Cancer Hospital

Poster

11:16 AM - 11:23 AM AST

Randomized Controlled Trial of Elenagen (Plasmid Encoding p62/SQSTM1) Plus Gemcitabine Versus Placebo Plus Gemcitabine in Patients With Platinum-Resistant Ovarian Cancer

Location: Exhibit Hall B

Poster Presenter: – McGill University Health Centre

Poster

11:00 AM - 11:02 AM AST

Introduction

Location: Exhibit Hall B

Moderator: – Nebraska Methodist Hospital

Moderator: – University of Virginia School of Medicine

11:02 AM - 11:09 AM AST

RARE CAMELLIAS: A feasibility study of a hybrid virtual platform to expand access to gynecologic oncology clinical trials in rural Louisiana

Location: Exhibit Hall B

Poster Presenter: – LSU Health New Orleans

Poster

11:09 AM - 11:16 AM AST

Growth is Good: Medicaid Expansion Positively Impacts Palliative Care and Survival in Gynecologic Cancers

Location: Exhibit Hall B

Poster Presenter: – Vanderbilt University School of Medicine

Poster

11:16 AM - 11:23 AM AST

An Opportunity to Improve HPV Vaccination Uptake among Youth: An Ob/Gyn Resident HPV Vaccination and Cervical Cancer Workshop among Local High School Students

Location: Exhibit Hall B

Poster Presenter: – University of California San Francisco School of Medicine

Poster

11:23 AM - 11:30 AM AST

Exploring the impact of 2018 Centers for Medicare & Medicaid Services National Coverage Determination of Next Generation Sequencing in Ovarian Cancer

Location: Exhibit Hall B

Poster Presenter: – University of Pennsylvania

Poster

11:00 AM - 12:00 PM AST

Exhibit Hall & Poster Tours

Location: Exhibit Hall B

11:00 AM - 12:00 PM AST

Poster Session 1

Location: Exhibit Hall B

Posters

11:15 AM - 11:35 AM AST

Build the Best Smart Phrases- and Other Resources to Boost Efficiency

Location: SGO Booth (#323)

Speaker: – Baylor College of Medicine

Speaker: – University of Oklahoma, Stephenson Cancer Center

Speaker: – Cleveland Clinic

11:30 AM - 11:32 AM AST

Introduction

Location: Exhibit Hall B

Moderator: – Ochsner Cancer Institute

Moderator: – Cleveland Clinic

11:32 AM - 11:39 AM AST

Hyperthermic intraperitoneal chemotherapy improves overall survival after cytoreduction in low-grade serous ovarian cancer

Location: Exhibit Hall B

Poster Presenter: – University of South Florida

Poster

11:39 AM - 11:46 AM AST

Long Term Follow Up for Cisplatin with or without Paclitaxel During Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Epithelial Ovarian Cancer at Interval Debulking Surgery (IDS)

Location: Exhibit Hall B

Poster Presenter: – The Cleveland Clinic

Poster

11:46 AM - 11:53 AM AST

From Prediction to Action: Simple Rules from a Preoperative Model to Guide MIS Conversion Risk in Advanced Ovarian Cancer

Location: Exhibit Hall B

Poster Presenter: – MD Anderson Cancer Center

Poster

11:53 AM - 12:00 PM AST

The association between allostatic load at the time of ovarian cancer debulking surgery and patient outcomes

Location: Exhibit Hall B

Poster Presenter: – Roswell Park Comprehensive Cancer Center

Poster

11:30 AM - 11:32 AM AST

Introduction

Location: Exhibit Hall B

Moderator:

Moderator: – University of Chicago

11:32 AM - 11:39 AM AST

Readability of Gynecologic Cancer Patient Education Materials From National Cancer Institute Designated Cancer Centers and Non-Profit Organizations

Location: Exhibit Hall B

Poster Presenter: – University of Minnesota

Poster

11:39 AM - 11:46 AM AST

Exercise interventions during and after the treatment of gynecologic cancers: A systematic review of randomized trials

Location: Exhibit Hall B

Poster Presenter: – University of Arizona, College of Medicine - Phoenix

Poster

11:46 AM - 11:53 AM AST

Patient-oncologist discordance in prognosistic understanding for patients with advanced or recurrent gynecologic cancer

Location: Exhibit Hall B

Poster Presenter: – Rush University

Poster

11:53 AM - 12:00 PM AST

Missed conversations: Gaps in sexual health counseling for premenopausal cervical cancer patients undergoing chemoradiation

Location: Exhibit Hall B

Poster Presenter: – NYU Langone Health

Poster

11:30 AM - 11:32 AM AST

Introduction

Location: Exhibit Hall B

Moderator: – University of Colorado

Moderator: – University of California, San Francisco

11:32 AM - 11:39 AM AST

LBA: Immunogenomic determinants of response to immune checkpoint inhibition in ovarian cancer: Insights from the NRG-GY003 clinical trial

Location: Exhibit Hall B

Speaker: – Icahn School of Medicine at Mount Sinai

LBA

11:39 AM - 11:46 AM AST

Targeting The IGF2BP3/MUC1/HIF-1α/Eno1 m6ADependent Metabolic Axis: A Novel Therapeutic Strategy In Endometrial Cancer

Location: Exhibit Hall B

Poster Presenter: – Fujian cancer hospital

Poster

11:46 AM - 11:53 AM AST

Tumor-targeted delivery of a VEGF-binding RNA aptamer by Listeria improves survival in a mouse model of ovarian cancer

Location: Exhibit Hall B

Poster Presenter: – Montefiore Medical Center/Albert Einstein College of Medicine

Poster

11:53 AM - 12:00 PM AST

High and stable MUC16 expression in endometrial cancer highlights potential for targeted antibody-drug conjugate development

Location: Exhibit Hall B

Poster Presenter: – Fred and Pamela Buffett Cancer Center at the University of Nebraska

Poster

11:45 AM - 12:00 PM AST

The Power of Lived Experience - Foundation for Women’s Cancer

Location: SGO Booth (#323)

Speaker:

12:00 PM - 12:02 PM AST

Introduction

Location: Ballroom A

Moderator: – Mayo Clinic

Moderator: – H.Lee Moffitt Cancer Center

12:02 PM - 12:08 PM AST

National utilization trends and efficacy of adjuvant treatment in low-grade endometrioid endometrial cancer patients with low volume lymph node metastases

Location: Ballroom A

Speaker: – University of Florida College of Medicine

12:08 PM - 12:14 PM AST

Adjuvant dostarlimab with pelvic radiation (RT) in locally advanced, mismatch repair-deficient (MMR-D) endometrial cancer (EC): D-RT Study

Location: Ballroom A

Speaker: – Memorial Sloan Kettering Cancer Center

12:14 PM - 12:20 PM AST

Primary results from the phase 2 endomERA study of giredestrant for patients with grade 1 endometrioid endometrial cancer

Location: Ballroom A

Speaker: – Mcgill University Health Centre, McGill University

12:20 PM - 12:28 PM AST

Distillation

Location: Ballroom A

Speaker: – The Ohio State University

12:28 PM - 12:34 PM AST

Four-year survival outcomes with dostarlimab plus chemotherapy in dMMR/MSI-H primary advanced or recurrent endometrial cancer in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial

Location: Ballroom A

Speaker: – Washington University School of Medicine

12:34 PM - 12:40 PM AST

Molecular Sub group and post immunotherapy Analysis: Results from NRG GY012

Location: Ballroom A

Speaker: – Sunnybrook Odette Cancer Centre/University of Toronto

12:40 PM - 12:48 PM AST

Distillation

Location: Ballroom A

Speaker: – Memorial Sloan Kettering Cancer Center

12:48 PM - 1:00 PM AST

Q&A

Location: Ballroom A

12:00 PM - 12:02 PM AST

Introduction

Location: 208

Moderator: – Cedars-Sinai Medical Center

Moderator: – The Southeast Permanente Medical Group

12:02 PM - 12:08 PM AST

Building Trust Through Community Partnerships: Improving Knowledge and Confidence in Clinical Trials Among African American and Hispanic Women

Location: 208

Speaker: – Northwestern

12:08 PM - 12:14 PM AST

Primary HPV Testing: A Cost-Saving, Equitable, and High-Impact Strategy for Cervical Cancer Screening in Underserved Populations

Location: 208

Speaker: – The University of Texas Health Science Center at Houston

12:14 PM - 12:20 PM AST

Barriers to Equity: Policy and System Gaps in Biomarker-Driven Gynecologic Cancer Trials Across the U.S.

Location: 208

Speaker: – Johns Hopkins University

12:20 PM - 12:28 PM AST

Distillation

Location: 208

Speaker: – Rutgers NJMS Newark

12:28 PM - 12:34 PM AST

Disparities in RVU Compensation Between Gynecologic Oncology and Surgical Oncology: Is There Structural Undervaluation?

Location: 208

Speaker: – University of Alabama Birmingham

12:34 PM - 12:40 PM AST

Gender and Geographic Disparity in Industry Payments to Gynecologic Oncologists in the United States

Location: 208

Speaker: – McGill University Health Centre

12:40 PM - 12:48 PM AST

Distillation

Location: 208

Speaker: – University Of Pennsylvania

12:48 PM - 1:00 PM AST

Q&A

Location: 208

12:00 PM - 12:02 PM AST

Introduction

Location: 104

Moderator: – Princess Margaret Hospital

Moderator: – University of Puerto Rico School of Medicine

12:02 PM - 12:05 PM AST

Integrated Single-cell Profiling Identifies TNFAIP3 as a Lactylation-Driven Regulator of Chemoresistance in Ovarian Cancer

Location: 104

Speaker: – Fudan University Shanghai Cancer Center

12:05 PM - 12:08 PM AST

Impact of CCNE1 amplification on progression-free and overall survival among patients with newly diagnosed ovarian cancer without a BRCA mutation

Location: 104

Speaker: – Memorial Sloan Kettering Cancer Center

12:08 PM - 12:11 PM AST

Profiling the Immune Repertoire in a Phase II Trial of Niraparib and Dostarlimab in Recurrent or Persistent Uterine Serous Carcinomas

Location: 104

Speaker: – The Ohio State University

12:11 PM - 12:14 PM AST

Combination of carboplatin and CHK1 inhibition to overcome platinum resistance in high grade serous ovarian cancer in preclinical mouse models

Location: 104

Speaker: – University of South Alabama, Mitchell Cancer Institute

12:14 PM - 12:24 PM AST

Distillation

Location: 104

Speaker: – University of California, San Diego

12:24 PM - 12:31 PM AST

Q&A

Location: 104

12:31 PM - 12:34 PM AST

Mirvetuximab soravtansine plus carboplatin in folate receptor alpha-expressing recurrent platinum-sensitive ovarian cancer

Location: 104

Speaker: – Dept. Of Medicine, UCLA

LBA

12:34 PM - 12:37 PM AST

Comprehensive Profiling of antibody-drug conjugate (ADC) Targets Reveals Histology-Specific and Co-Expression Patterns in Endometrial Carcinoma

Location: 104

Speaker: – Saitama Medical University International Medical Center

12:37 PM - 12:40 PM AST

A global, phase 1/2 study of DB1311/BNT324 (a novel B7H3 ADC) monotherapy in patients with previously treated advanced cervical cancer or platinum-resistant recurrent ovarian cancer: Outcomes by prior treatment

Location: 104

Speaker: – Wayne State University

12:40 PM - 12:43 PM AST

Epigenetic drivers of FOLR expression in high grade serous carcinoma

Location: 104

Speaker: – University of Colorado Anschutz Medical Campus

12:43 PM - 12:53 PM AST

Distillation

Location: 104

Speaker: – The University of Oklahoma Health Sciences Center

12:53 PM - 1:00 PM AST

Q&A

Location: 104

12:00 PM - 12:05 PM AST

Introduction

Location: Ballroom B

Moderator: – University of Colorado

12:05 PM - 12:10 PM AST

Onramp

Location: Ballroom B

Speaker: – Holy Cross Hospital in Fort Lauderdale

12:10 PM - 12:20 PM AST

ADAPT (ADA)

Location: Ballroom B

12:20 PM - 12:25 PM AST

Demo Part 1

Location: Ballroom B

Speaker: – University of Colorado

Speaker: – Holy Cross Hospital in Fort Lauderdale

12:25 PM - 12:35 PM AST

ADAPT (PT)

Location: Ballroom B

Speaker: – University of Colorado, Denver

12:35 PM - 12:45 PM AST

Demo Part 2

Location: Ballroom B

Speaker: – University of Colorado

Speaker: – Holy Cross Hospital in Fort Lauderdale

12:45 PM - 12:55 PM AST

Pitfalls

Location: Ballroom B

Speaker: – University of Colorado

Speaker: – Holy Cross Hospital in Fort Lauderdale

Speaker: – University of Colorado, Denver

12:55 PM - 1:00 PM AST

Closing Remarks

Location: Ballroom B

12:00 PM - 12:02 PM AST

Introduction

Location: 209

Moderator: – Montefiore Medical Center

12:02 PM - 12:05 PM AST

Audience Poll

Location: 209

Speaker: – Rutgers - NJMS

12:05 PM - 12:15 PM AST

Challenges and opportunities with screening: The Puerto Rico story

Location: 209

Speaker: – University of Puerto Rico School of Medicine, University of Puerto Rico Comprehensive Cancer Center

12:15 PM - 12:27 PM AST

Leveraging Your Registry through the NCDB Cervix Cancer Quality Measure

Location: 209

Speaker: – UCSF Helen Diller Family Comprehensive Cancer Center

Speaker: – University of Alabama at Birmingham

12:27 PM - 12:39 PM AST

Global perspective: What's working well

Location: 209

Speaker: – Memorial Sloan Kettering Monmouth

12:37 PM - 12:49 PM AST

Equitable Implementation: Redesigning Cervical Cancer Care Pathways

Location: 209

Speaker: – Rutgers NJMS Newark

12:49 PM - 1:00 PM AST

Q&A

Location: 209

1:30 PM - 3:00 PM AST

ISS XI: Expert Second Opinion: Investigators Provide Perspectives on the Best-Practice Management of Ovarian Cancer

Location: Ballroom A

1:30 PM - 3:00 PM AST

ISS XII: A Treatment Option for Patients With Primary Advanced or Recurrent Endometrial Cancer

Location: Ballroom B

1:30 PM - 3:00 PM AST

ISS XIII: Cases and Conversations™: Redefining Treatment Pathways in Low-Grade Serous Ovarian Cancer

Location: 208

1:30 PM - 3:00 PM AST

ISS XIV: Data + Perspectives: The Potential Role of TROP2- and CDH6-Directed Antibody-Drug Conjugates in Gynecologic Cancers

Location: 209

1:30 PM - 4:30 PM AST

KSGO/JSGO/SGO Joint Session: Ovarian Cancer

Location: 102AB

1:30 PM - 1:35 PM AST

Welcome & Introduction

Location: 102AB

Moderator:

Moderator: – UC Davis Health

Moderator: – Seoul National University Bundang Hospital

1:35 PM - 1:55 PM AST

PDS vs. NAC-IDS (TRUST trial)

Location: 102AB

Speaker: – Memorial Sloan-Kettering Cancer Center

1:55 PM - 2:15 PM AST

Robotic debulking for advanced ovarian cancer

Location: 102AB

Speaker: – Center of Hope Reno

2:15 PM - 2:30 PM AST

HIPEC for advanced ovarian cancer

Location: 102AB

Speaker: – Ajou University Hospital

2:30 PM - 2:40 PM AST

Discussion

Location: 102AB

Speaker:

Speaker: – Yonsei University College Of Medicine

Speaker:

Speaker: – University of South Florida

2:40 PM - 2:55 PM AST

Break & Group Photo

2:55 PM - 3:15 PM AST

Prioritizing: PARPi, ICI, Bev, ADC

Location: 102AB

Speaker: – Saitama Medical University International Medical Center

3:15 PM - 3:35 PM AST

Elahere in Real World: USA

Location: 102AB

Speaker: – Inova Schar Cancer Institute

3:35 PM - 3:45 PM AST

Discussion

Location: 102AB

Speaker: – Korea University College of Medicine Guro Hospital

Speaker: – Sung Kyun Kwan University of Medicine

Speaker:

Speaker: – Konkuk University Hospital

3:45 PM - 3:55 PM AST

Break

Location: 102AB

3:55 PM - 4:30 PM AST

Tumor Board

Location: 102AB

Speaker: – Seoul National University College of Medicine

Speaker: – National Cancer Center Hospital

3:00 PM - 3:02 PM AST

Introduction

Location: Exhibit Hall B

Moderator: – City of Hope

Moderator: – Dana-Farber Cancer Insitute

3:02 PM - 3:09 PM AST

Feasibility and Adherence to Cognitive Training in Gynecologic Cancer Patients with Cancer-Related Cognitive Impairment

Location: Exhibit Hall B

Poster Presenter: – Northwestern University Feinberg School of Medicine

Poster

3:09 PM - 3:16 PM AST

Real-world safety profile and clinical management of patients (pts) with epithelial ovarian cancer (EOC) who received first-line maintenance (1LM) niraparib therapy: final results from the 1NSPIRE chart review study

Location: Exhibit Hall B

Poster Presenter: – Indiana University

Poster

3:16 PM - 3:23 PM AST

All Welcome: Age and Frailty Do Not Impact Mirvetuximab Safety or Efficacy

Location: Exhibit Hall B

Poster Presenter: – The Ohio State University

Poster

3:23 PM - 3:30 PM AST

Elevated Uterine Cancer Incidence Among Women with Intellectual and Developmental Disabilities: Insights into Gynecologic Cancer Inequities

Location: Exhibit Hall B

Poster Presenter: – The Catholic University Of Korea

Poster

3:00 PM - 3:02 PM AST

Introduction

Location: Exhibit Hall B

Moderator: – University of Virginia

Moderator: – Roswell Park Comprehensive Cancer Center

3:02 PM - 3:09 PM AST

PTEN as a biomarker for sensitivity to multitargeted small molecule CDK4/6-CDK9-AURKA/B inhibitor, LCI133, and other CDK9 inhibitors

Location: Exhibit Hall B

Poster Presenter: – Levine Cancer Institute, Atrium Health

Poster

3:09 PM - 3:16 PM AST

Performance of an extracellular vesicle and particle (EVP) based ovarian cancer (OC) screening test in average risk postmenopausal woman up to 3 years prior to clinical diagnosis

Location: Exhibit Hall B

Poster Presenter: – Mercy Bioanalytics

Poster

3:16 PM - 3:23 PM AST

Relacorilant plus nab-paclitaxel demonstrates a progression-free survival benefit in ovarian cancer independent of tumor glucocorticoid receptor (GR) expression levels

Location: Exhibit Hall B

Presenter: – University of pittsburgh

Poster

3:23 PM - 3:30 PM AST

Higher allostatic load is associated with reduced overall survival in women with epithelial ovarian cancer

Location: Exhibit Hall B

Poster Presenter: – University of Pittsburgh School of Medicine

Poster

3:00 PM - 3:30 PM AST

Surgical Film Tour Group: Surgical Video Walk

Location: SGO Booth (#323)

Surgical Films

3:00 PM - 3:02 PM AST

Introduction

Location: Exhibit Hall B

Moderator: – The Cleveland Clinic

3:02 PM - 3:16 PM AST

Minimally Invasive Vascular Injury Repair: An Educational Video Series

Location: Exhibit Hall B

Surgical Film Tour Presenter: – Duke University

3:16 PM - 3:30 PM AST

Laparoscopic Radical Hysterectomy with Internal Iliac Vessel Resection and Ureteral Reimplantation for Low-Grade Endometrial Stromal Sarcoma

Location: Exhibit Hall B

Surgical Film Tour Presenter: – McGill University

3:00 PM - 5:00 PM AST

Exhibit Hall | Poster Tours | Surgical Film Tour

Location: Exhibit Hall B

3:30 PM - 4:00 PM AST

Vibe Shifting our Medical Vibe Coding: Theory and Context Behind our Billing and Coding System

Location: Fellows' Lounge - Exhibit Hall B

Speaker:

3:40 PM - 4:00 PM AST

Building the Next Decade Together: Policy, Coding, and Quality

Location: SGO Booth (#323)

Speaker: – Penn State Hershey Medical Center

3:45 PM - 3:47 PM AST

Introduction

Location: Exhibit Hall B

Moderator: – University Of Pennsylvania

Moderator: – University of Arkansas for Medical Sciences

3:47 PM - 3:54 PM AST

Overutilization of laboratory studies on paracentesis and thoracentesis specimens in patients with gynecologic malignancies: An opportunity to reduce waste and cost from unindicated laboratory testing

Location: Exhibit Hall B

Poster Presenter: – Cedars Sinai

Poster

3:54 PM - 4:01 PM AST

30- and 90-day percutaneous nephrostomy (PCN) tube associated complications in patients with locally advanced, metastatic, or recurrent cervical cancer

Location: Exhibit Hall B

Poster Presenter: – University of Texas Southwestern

Poster

4:01 PM - 4:08 PM AST

Temporal trends in the cost of adverse events (AEs) in patients with primary advanced or recurrent endometrial cancer (pA/R EC) in the ENGOT-EN-6-NSGO/GOG-3031/RUBY trial

Location: Exhibit Hall B

Poster Presenter: – Women and Infants Hospital Brown University

Poster

4:08 PM - 4:15 PM AST

Efficacy and safety of fam-trastuzumab deruxtecan in recurrent HER2-positive endometrial cancer

Location: Exhibit Hall B

Poster Presenter: – Memorial Sloan Kettering Cancer Center

Poster

3:45 PM - 3:47 PM AST

Introduction

Location: Exhibit Hall B

Moderator: – The Cleveland Clinic Foundation

Moderator: – Duke University, Durham, NC

3:47 PM - 3:54 PM AST

Transversus Abdominis Plane Block Compared to Local Anesthetic Wound Infiltration in Gynecologic Oncology Surgery

Location: Exhibit Hall B

Poster Presenter: – University of Wisconsin - Madison

Poster

3:54 PM - 4:01 PM AST

Rationale and Study Design of the KOV-HIPEC-02R (RECOVER):A Randomized, Multicenter, Open-label Phase III trial of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Platinum-Resistant Recurrent

Location: Exhibit Hall B

Poster Presenter: – National Cancer Center

Poster

4:01 PM - 4:08 PM AST

Laparoscopic Cytoreduction after Neoadjuvant Chemotherapy in High-Grade Epithelial Ovarian Cancer: LANCE Randomized Clinical Trial

Location: Exhibit Hall B

Poster Presenter: – MD Anderson Cancer Center

Poster

4:08 PM - 4:15 PM AST

The BHFS Study (Better, Harder, Faster, Stronger): Does Neoadjuvant Chemotherapy Improve Fitness for Surgery?

Location: Exhibit Hall B

Poster Presenter: – Atrium Health Wake Forest Baptist

Poster

4:00 PM - 4:45 PM AST

Poster Session 2

Location: Exhibit Hall B

Posters

4:10 PM - 4:30 PM AST

HABE you heard of health equity? A presentation from the Healthcare Access, Belonging & Engagement Committee

Location: SGO Booth (#323)

Speaker: – Women's Cancer Care Associates

Speaker: – University of Miami

4:30 PM - 4:32 PM AST

Introduction

Location: Exhibit Hall B

Moderator: – University of North Carolina School of Medicine

Moderator: – Brigham & Women's Hospital/Dana Farber Cancer Institute

4:32 PM - 4:39 PM AST

A phase 3, randomized, open-label study of trastuzumab deruxtecan versus standard-of-care chemotherapy as adjuvant treatment for patients with HER2-expressing (IHC 3+/2+) endometrial cancer: DESTINY-Endometrial02 (DEâ€‘02)

Location: Exhibit Hall B

Poster Presenter: – Women & Infants Hospital/Brown University

Poster

4:39 PM - 4:46 PM AST

GOG-3119/ENGOT-en29/TroFuse-033: A Phase 3, Randomized Study of Sacituzumab Tirumotecan Plus Pembrolizumab vs Pembrolizumab Alone as First-Line Maintenance Therapy for Mismatch Repair-Proficient Endometrial Cancer

Location: Exhibit Hall B

Poster Presenter: – Florida Cancer Specialists and Research Institute

Poster

4:46 PM - 4:53 PM AST

[Encore] Randomized phase III study of first-line (1L) trastuzumab deruxtecan (T-DXd) with rilvegostomig or pembrolizumab in patients with HER2-expressing, mismatch repair-proficient (pMMR), primary advanced or recurrent endometrial cancer

Location: Exhibit Hall B

Poster Presenter: – Memorial Sloan Kettering Cancer Center

Poster

4:53 PM - 5:00 PM AST

Sapanisertib and serabelisib (PIKTOR) with paclitaxel, and an insulin-suppressing diet (ISD) substudy, in patients with advanced/recurrent endometrial cancer (EC): GOG-3111

Location: Exhibit Hall B

Poster Presenter: – Mount Sinai Medical Center

Poster

4:30 PM - 4:32 PM AST

Introduction

Location: Exhibit Hall B

Moderator: – Dana-Farber Cancer Institute

4:32 PM - 4:39 PM AST

Torvutatug samrotecan (AZD5335) vs mirvetuximab soravtansine gynx in high FRÎ± expressing tumors and torvutatug samrotecan vs chemotherapy in low FRÎ± expressing tumors in patients with platinum resistant epithelial ovarian cancer in the randomized Phase III TREVI OC 01/GOG 3127/ENGOT ov93 trial

Location: Exhibit Hall B

Poster Presenter: – European Institute of Oncology

Poster

4:39 PM - 4:46 PM AST

RAINFOL-04 (ENGOT-OV96/GOG-3134): A phase 3, open-label, randomized study of rinatabart sesutecan plus standard of care (SOC) vs SOC as maintenance treatment after second-line platinum-based chemotherapy in patients with recurrent platinum-sensitive ovarian cancer

Location: Exhibit Hall B

Poster Presenter: – University Hospital Leuven, KU Leuven

Poster

4:46 PM - 4:53 PM AST

A Phase 1/2 study of REGN5668, a MUC16×CD28 costimulatory bispecific antibody, in combination with other targeted therapies, in patients with recurrent ovarian or endometrial cancer: Trial in progress update

Location: Exhibit Hall B

Poster Presenter: – Memorial Sloan Kettering Cancer Center

Poster

4:53 PM - 5:00 PM AST

BELLA: a phase 2 study of relacorilant plus nab-paclitaxel +/- bevacizumab in patients with gynecologic cancers

Location: Exhibit Hall B

Poster Presenter: – Humanitas San Pio X Hospital

Poster

4:30 PM - 4:32 PM AST

Introduction

Location: Exhibit Hall B

Moderator: – University of Alabama at Birmingham

Moderator: – Inova Schar Cancer Institute

4:32 PM - 4:39 PM AST

Phase I Clinical Trial Assessing the Safety and Feasibility of Intramuscular pNGVL4a-CRTE6E7L2 and TA-CIN Administration for the Treatment of Patients with HPV16+ Atypical Squamous Cells of Unknown Significance (ASC-US) or Low-Grade Squamous Intraepithelial Lesion (LSIL)

Location: Exhibit Hall B

Poster Presenter: – University of Alabama at Birmingham

Poster

4:39 PM - 4:46 PM AST

A Feasibility Study of E7 TCR-T Cell Induction Therapy for Locoregionally Advanced HPVAssociated Cancers

Location: Exhibit Hall B

Poster Presenter: – Rutgers Cancer Institute

Poster

4:46 PM - 4:53 PM AST

A Phase II Trial of T Cell Receptor Gene Therapy Targeting HPV-16 E7 for HPV-Associated Cancers

Location: Exhibit Hall B

Poster Presenter: – Rutgers Cancer Institute

Poster

4:53 PM - 5:00 PM AST

A Phase I Open Label, Dose Escalation Clinical Trial Assessing the Safety, Tolerability, and Feasibility of pNGVL4aCRTE6E7L2 HPV DNA Vaccine Administration Via Intramuscular TriGrid Electroporation Delivery System to Patients with HPV16+ High-Grade Cervical Intraepithelial NeoplasiaÂ

Location: Exhibit Hall B

Poster Presenter: – Johns Hopkins University

Poster

4:30 PM - 4:32 PM AST

Introduction

Location: Exhibit Hall B

Moderator: – MD Anderson Cancer Center

Moderator: – Memorial Sloan Kettering Cancer Center

4:32 PM - 4:39 PM AST

Combination targeted and Hormonal treAtMEnt of Low-gradE serous Ovarian cancer in the upfroNt setting (CHAMELEON)

Location: Exhibit Hall B

Poster Presenter: – Emory University School Of Medicine

Poster

4:39 PM - 4:46 PM AST

Obrixtamig (BI 764532) in patients with relapsed/refractory delta-like ligand 3 (DLL3)-high expressing extrapulmonary neuroendocrine carcinoma (epNEC): trial in progress of the dose-expansion part of the phase II DAREON-5 trial

Location: Exhibit Hall B

Poster Presenter: – Boehringer Ingelheim

Poster

4:46 PM - 4:53 PM AST

A Phase Ib/II Single Arm Study of Cabozantinib Plus Dostarlimab in Women with Recurrent Gynecologic Carcinosarcoma

Location: Exhibit Hall B

Poster Presenter: – University of Alabama at Birmingham

Poster

4:40 PM - 4:55 PM AST

SGO Resources You May Not Know About: A Quick Tour for Trainees & Early-Career Members

Location: SGO Booth (#323)

Speaker: – McGaw Medical Center of Northwestern University

Speaker: – Inova Health System, Walter Reed National Military Medical Center

Speaker: – Northwestern University Feinberg School of Medicine

5:00 PM - 5:30 PM AST

Transition Break | Tumor Board Bar Open

Location: Exhibit Hall A

5:30 PM - 7:00 PM AST

Tumor Board

Location: Exhibit Hall A

Live Streamed

7:00 PM - 9:00 PM AST

Alumni Events & Receptions

Location: Various Locations